Business Wire

Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting Formulation of S-892216, an Antiviral for COVID-19 Pre-Exposure Prophylaxis in ...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced Shionogi Inc., a New Jersey-based ...
News Medical

Could neutralizing SARS-CoV-2 monoclonal antibodies pre-exposure prophylaxis be cost-effective in a population at risk for severe COVID-19?

A recent study published in JAMA Network Open evaluated the cost-effectiveness of monoclonal antibodies (mAbs) as pre-exposure prophylaxis (PrEP) for coronavirus disease 2019 (COVID-19). Study: Health ...
EurekAlert!

HIV pre-exposure prophylaxis works but needs regular testing

HIV pre-exposure prophylaxis (PrEP) is a prevention strategy which includes the regular or event-driven use of antiretroviral medication to prevent HIV infection in adults. Several clinical trials ...
News Medical

New oral antiretroviral shows potential as long-acting HIV pre-exposure prophylaxis

A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, USA, ...
Opinion
R Street InstituteOpinion

R Street Testimony in Support of GA SB 195, Authorizing pharmacists to dispense preexposure prophylaxis and postexposure prophylaxis under certain conditions

Chelsea Boyd, Research Fellow, Integrated Harm Reduction, R Street Institute In SUPPORT of Senate Bill 195, “Pharmacies; pharmacists are authorized to dispense preexposure prophylaxis and postexposure ...
Medical Xpress

Exploring the relationship between HIV pre-exposure prophylaxis and the incidence of chlamydia, gonorrhea and syphilis

In their research article published in Eurosurveillance, von Schreeb et al. challenge existing assumptions regarding the relationship between the use of HIV pre-exposure prophylaxis (PrEP) and the ...
Seeking Alpha

ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program

MONTRÉAL, March 25, 2025 /CNW/ - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (PFE) and Shionogi as shareholders, is pleased to ...